A. PP2Ce and PP2Cα expression in NRVM following ISO treatment. B. PP2Ce expression in NRVM treated with ISO (1μM) with or without co-treatment of proteasome inhibitor MG132 (10μM) or lysosomal inhibitor BAF (50nM) as indicated. C. Quantification of PP2Ce expression in NRVM treated with ISO with or without additional treatment of cycloheximide (CHX), MG132 or BAF as indicated. n: number of total experimental replicates, *: p< 0.05, **: p<0.01. D. PP2Ce expression in NRVM treated ISO or forskolin (FSK) at 0.1, 1, and 10μM concentrations as indicated. E. PP2Ce expression in NRVM treated with FSK (1μM) with or without PKA inhibitor H89 (1μM) as indicated.